Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle — Overview, Diagnosis & Treatment Options | MyMedicPlus

Leiomyosarcoma (LMS) is a malignant smooth muscle tumor representing 5-10% of all soft tissue sarcomas. Common primary sites include the uterus (most common, approximately 40% of all LMS), retroperitoneum, large blood vessels (IVC, femoral vein), and extremities. Approximately 2,000 new US cases are diagnosed annually. Uterine LMS accounts for 1-2% of all uterine malignancies but causes 25-35% of uterine cancer deaths due to its aggressive behavior. Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle to help patients understand the condition, its causes, symptoms, and available treatment options. This page provides evidence-based clinical information to help patients and caregivers understand this condition, its risk factors, symptoms, and available treatment options from accredited medical sources.

Most LMS cases are sporadic without identifiable cause. Prior radiation therapy to the pelvis increases the risk of radiation-induced sarcoma, including LMS, with a latency period of 5-30 years. Li-Fraumeni syndrome (TP53 germline mutation) predisposes to sarcomas including LMS. Tamoxifen use has been associated with an increased risk of uterine sarcomas. IDH mutations and PTEN deletions are common somatic events. ATRX mutations are present in approximately 25% of LMS and associated with alternative lengthening of telomeres (ALT). No environmental or dietary risk factors are firmly established. The causes of Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

Uterine LMS presents with abnormal uterine bleeding, pelvic pain or pressure, rapid uterine enlargement, and postmenopausal uterine mass. Retroperitoneal LMS causes diffuse abdominal or back pain, an enlarging abdominal mass, and gastrointestinal or urinary symptoms from compression of adjacent structures. Extremity LMS presents as a deep enlarging soft tissue mass, which may be painless initially. Constitutional symptoms (weight loss, fatigue) indicate advanced or metastatic disease. Large tumors may compress adjacent neurovascular structures. Symptoms of Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

MRI with gadolinium is the preferred imaging modality for local staging, delineating tumor borders, vascular involvement, and compartmentalization. CT of chest, abdomen, and pelvis evaluates for pulmonary and hepatic metastases. Core needle biopsy in the resection plane provides tissue for FNCLCC grade, smooth muscle actin, desmin, and h-caldesmon immunohistochemistry. Molecular testing for ATRX, IDH1/2, and TP53 aids diagnosis and may predict behavior. AJCC 8th edition soft tissue sarcoma TNM staging applies. FDG-PET may be used for assessing treatment response and detecting metastases. Diagnosis of Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Wide surgical excision with negative margins (R0 resection) is the primary treatment. Uterine LMS: total hysterectomy plus bilateral salpingo-oophorectomy (BSO); lymphadenectomy does not improve survival. Perioperative radiation is considered for high-risk retroperitoneal or extremity LMS. Adjuvant chemotherapy for high-risk LMS (doxorubicin plus ifosfamide or gemcitabine plus docetaxel for uterine LMS) is used based on institutional practice but without definitive Level 1 evidence. Metastatic LMS: doxorubicin monotherapy or in combination; gemcitabine plus docetaxel (particularly for uterine LMS); trabectedin; eribulin; pazopanib; dacarbazine. Treatment of Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

Five-year overall survival: localized extremity LMS approximately 50-70%; retroperitoneal LMS approximately 30-40% (due to difficulty achieving R0 margins); uterine LMS localized approximately 40-55%, advanced approximately 10-25%. High FNCLCC grade and retroperitoneal location are the strongest adverse prognostic factors. Approximately 50-70% of patients with localized high-grade LMS develop distant metastases within 2-3 years. Selected patients with isolated pulmonary metastases may benefit from metastatectomy, with 2-year post-resection survival of approximately 25-30%. The prognosis for Leiomyosarcoma: Soft Tissue Sarcoma of Smooth Muscle varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

No established prevention strategy exists for sporadic LMS. Unnecessary pelvic radiation should be avoided to minimize radiation-induced sarcoma risk. Patients with Li-Fraumeni syndrome (TP53 germline mutation) require annual whole-body MRI surveillance. The rare risk that a uterine mass is LMS (approximately 1 in 2,000) does not justify prophylactic hysterectomy for all fibroids, but rapid growth or atypical features should prompt investigation. Power morcellation should be avoided in presumed myomectomy or hysterectomy for fibroids due to the risk of disseminating occult uterine sarcoma.

Go to the ER immediately for acute abdomen from retroperitoneal LMS haemorrhage, or profuse uterine haemorrhage from a rapidly enlarging presumed fibroid. See a specialist urgently for a postmenopausal uterine mass or a premenopausal uterus enlarging unusually rapidly; abnormal uterine bleeding in a woman with a known uterine mass particularly if growth has accelerated; or a deep soft tissue mass greater than 5 cm or increasing in size in the extremity or abdomen — refer to a sarcoma centre before any excision. Power morcellation should be withheld until LMS is excluded. Li-Fraumeni syndrome (TP53 germline mutation) carriers require annual whole-body MRI surveillance. Post-treatment patients need regular chest CT to detect pulmonary metastases, the predominant relapse site.